驱动基因阴性的晚期非小细胞肺癌放免联合治疗研究进展  

Research Progress on Combination of Radiotherapy and Immunotherapy on Advanced Non-small Cell Lung Cancer with Negative Driver Genes

作　　者：李朋 吴晓婷 宫晓梅[1] LI Peng;WU Xiaoting;GONG Xiaomei(Department of Radiation Oncology,Shanghai Pulmonary Hospital,Tongji University,Shanghai 200433,China)

机构地区：[1]同济大学附属上海市肺科医院放疗科,上海200433

出　　处：《肿瘤防治研究》2023年第9期842-846,共5页Cancer Research on Prevention and Treatment

摘　　要：非小细胞肺癌(NSCLC)患者中有很大比例在发现时被诊断为转移性和不可治愈的晚期肺癌,以致于失去了手术的机会,5年生存率较低。免疫治疗时代,众多种类的免疫检查点抑制剂被批准用于驱动基因阴性的晚期NSCLC患者的一/二线治疗,同时与放疗联合作为晚期NSCLC患者的重要治疗策略。放射治疗与免疫治疗相结合的创新策略在临床研究中获得了大量的可行性证据。在分子和细胞水平上观察免疫机制的临床前实验初步揭示了肿瘤、辐射和免疫系统之间的相互作用。本文对放免联合治疗在驱动基因阴性晚期NSCLC治疗中的进展进行简要综述。A large proportion of patients with non-small cell lung cancer(NSCLC)are diagnosed with metastatic and incurable advanced lung cancer at the time of discovery,so these patients are given no surgical opportunity and have a low 5-year survival rate.In the era of immunotherapy,many kinds of immune checkpoint inhibitors(ICIs)have been approved as the first/second-line treatment for patients with advanced NSCLC with negative driving genes and have been combined with radiotherapy as an important treatment strategy for patients with advanced NSCLC.The innovative strategy of combining radiotherapy and immunotherapy has shown feasibility as supported by practical evidence in clinical research.A preclinical experiment of observing the immune mechanism at the molecular and cellular levels preliminarily revealed the interaction among tumor,radiation,and immune system.This paper briefly reviews the progress of combined radiotherapy and immunotherapy in the treatment of advanced NSCLC with negative drvier genes.

关 键 词：晚期非小细胞肺癌 驱动基因阴性 放免联合治疗 

分 类 号：R734.2[医药卫生—肿瘤]